Spain

Adaptam Therapeutics secures €3M to develop new Cancer Immunotherapies Targeting Immune Suppression
Emerging biotech Adaptam Therapeutics has raised €3 million in pre-seed funding to advance a new class of cancer immunotherapies that target immunosuppressive myeloid cells, a key driver of resistance in solid tumors.

The best Articles in our Network